Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms.
Plasma amantadine concentrations were assessed in a series of hospitalized schizophrenic patients receiving this drug during a double-blind trial of amantadine and benztropine in the treatment of neuroleptic-induced extrapyramidal symptoms (EPS). Mean (+/- S.E.) plasma amantadine concentrations were 0.54 +/- 0.08 microgram/ml on day 7 and 0.43 +/- 0.08 microgram/ml on day 14. Overall improvement of EPS was not correlated with plasma level, but improvement in the target EPS of rigidity was correlated with plasma amantadine concentration on day 7 (r = 0.75) and day 14 (r = 0.68). There was no evidence that the overall improvement in schizophrenic symptomatology was influenced by plasma amantadine concentrations.
D000547:Amantadine / Q000378:metabolism* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007700:Kinetics; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy; D013997:Time Factors
D000547:Amantadine